Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRT-2359 in MYC-driven solid tumors and DLBCL
NCT05546268Phase 2Active, not recruiting
- Sponsor
- Monte Rosa Therapeutics
- Start
- Oct 2022
- Primary completion
- May 2026
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
A Phase 2 trial of MRT-2359 in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), neuroendocrine cancer, diffuse large B-cell lymphoma (DLBCL), breast cancer, sponsored by Monte Rosa Therapeutics. Started Oct 2022; status: active, not recruiting.
02
Drugs
MRT-2359
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)neuroendocrine cancerdiffuse large B-cell lymphoma (DLBCL)breast cancer
Beyond the preview
Go deeper on NCT05546268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05546268.